ASTRAZENECA

New test may turn AZ`s Lynparza into precision drug for prostate cancer

New test may turn AZ`s Lynparza into precision drug for prostate cancer

Published 18/06/2017

FILE PHOTO: The logo of AstraZeneca is seen on a medication package in a pharmacy in London, Britain, April 28, 2014. REUTERS/Stefan Wermuth/File Photo

Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca's drug Lynparza into a precision medicine for prostate cancer.

[more…]

Newer type 2 diabetes drugs show heart protective quality in study

Newer type 2 diabetes drugs show heart protective quality in study

Published 19/03/2017

A newer class of type 2 diabetes drugs significantly cut the risk of death and hospitalization for heart failure compared with other medicines for the disease, according to data released on Sunday from a so-called real world study sponsored by AstraZeneca.

[more…]

AstraZeneca receives fresh blow to potassium drug

AstraZeneca receives fresh blow to potassium drug

Published 17/03/2017

FILE PHOTO: The logo of AstraZeneca is seen on a medication package at a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth/File Photo

AstraZeneca said on Friday that U.S. regulators had rejected the British company's new drug for high potassium levels, in the latest setback to the product.

[more…]

AstraZeneca ovarian cancer drug slows disease markedly in study

AstraZeneca ovarian cancer drug slows disease markedly in study

Published 14/03/2017

A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble

AstraZeneca's ovarian cancer drug Lynparza slashed the risk of disease progression in a closely watched clinical trial, boosting its profile against rivals within the novel PARP inhibitor drug class.

[more…]

AstraZeneca resolves Faslodex patent litigation in U.S.

AstraZeneca resolves Faslodex patent litigation in U.S.

Published 13/07/2016

British drugmaker AstraZeneca Plc said on Wednesday it has entered into an agreement with Sandoz, the generic pharmaceuticals division of Novartis AG, to resolve Faslodex [more…]

AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep

AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep

Published 21/04/2016

CAMBRIDGE, England AstraZeneca, working with genome pioneer Craig Venter, is launching a massive gene hunt in the most comprehensive bet yet by a pharmaceutical firm [more…]

Sanofi poaches AstraZeneca scientist as new research head

Sanofi poaches AstraZeneca scientist as new research head

Published 29/03/2016

LONDON French drugmaker Sanofi has poached one of AstraZeneca's top scientists to be its new research head in another high-profile departure for the British drugmaker.

[more…]

AstraZeneca buys most of Acerta for $4 billion to add cancer drug

AstraZeneca buys most of Acerta for $4 billion to add cancer drug

Published 17/12/2015

LONDON AstraZeneca (AZN.L) said on Thursday it had agreed to buy 55 percent stake of privately held biotech firm Acerta Pharma for $4 billion to [more…]

FDA panel votes in favor of approving AstraZeneca’s gout drug

FDA panel votes in favor of approving AstraZeneca’s gout drug

Published 23/10/2015

An independent panel of advisers to the U.S. Food and Drug Administration on Friday voted 10-4 in favor of approving AstraZeneca Plc's gout drug.

All [more…]

AstraZeneca names Genentech’s Bohen as chief medical officer

AstraZeneca names Genentech’s Bohen as chief medical officer

Published 24/08/2015

LONDON British pharmaceutical company AstraZeneca named Sean Bohen as its chief medical officer, in an appointment that it said could help accelerate the development of [more…]